Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience

B. Weinbergerová, I. Demel, B. Víšek, J. Válka, M. Čerňan, P. Jindra, J. Novák, L. Stejskal, F. Kovácsová, T. Kabut, T. Szotkowski, R. Hájek, P. Žák, P. Cetkovský, Z. Král, J. Mayer

. 2022 ; 40 (2) : 280-286. [pub] 20220217

Language English Country Great Britain

Document type Letter, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc22018968

COVID-19 significantly impairs survival rates among hematological patients when compared to the general population. Our prospective multicentre project analyzed early administration of anti-SARS-CoV-2 spike protein neutralizing monoclonal antibodies (NmAbs) - bamlanivimab (72%) and casirivimab/imdevimab (28%) - efficacy among hematological patients with early-stage COVID-19. Mortality rate was compared to a control cohort of 575 SARS-CoV-2 positive hematological patients untreated with any specific anti-COVID-19 therapy. 88 hematological patients with lymphomas, acute leukemias, and myeloma as their most frequent underlying diagnoses (72%) were evaluated with a 97 days median follow-up after NmAb administration. One third of patients (32%) were treated with an anti-CD20 monoclonal antibody before COVID-19 diagnosis. Median time between first COVID-19 symptom and NmAb administration was 2 days. When administering NmAb, 29%, 57%, 11%, 2%, and 1% of our patients had asymptomatic, mild, moderate, severe, and critical degrees of COVID-19, respectively. 80% of baseline asymptomatic patients remained asymptomatic following NmAb administration. Median duration of COVID-19 symptoms after NmAb administration was 2.5 days. Progression to severe/critical COVID-19 occurred among a total of 17% (15/88) of our cases and numerically higher with bamlanivimab versus casirivimab/imdevimab (21% vs. 8%; p = 0.215), and myelomas (29%), lymphomas (17%) and acute leukemias (18%), respectively. During final follow-up, nine deaths (10%) were recorded - all after bamlanivimab (p = 0.056) with 8% attributed to COVID-19. Regarding "remdesivir/convalescent plasma naïve" patients, COVID-19 mortality rates were significantly lower in our NmAbs treated cohort compared to the control cohort of untreated SARS-CoV-2 positive hematological patients (6% vs. 16%, p = 0.020), respectively. Our study validated the safety and efficacy of NmAbs early use among hematological patients with newly diagnosed early-stage COVID-19 in terms of alleviating infection course and decreasing mortality. Results confirmed a more positive effect of a casirivimab/imdevimab combination versus bamlanivimab monotherapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018968
003      
CZ-PrNML
005      
20220804135226.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/hon.2974 $2 doi
035    __
$a (PubMed)35120267
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Weinbergerová, Barbora $u Department of Internal Medicine - Hematology and Oncology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic $1 https://orcid.org/0000000164602471
245    10
$a Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience / $c B. Weinbergerová, I. Demel, B. Víšek, J. Válka, M. Čerňan, P. Jindra, J. Novák, L. Stejskal, F. Kovácsová, T. Kabut, T. Szotkowski, R. Hájek, P. Žák, P. Cetkovský, Z. Král, J. Mayer
520    9_
$a COVID-19 significantly impairs survival rates among hematological patients when compared to the general population. Our prospective multicentre project analyzed early administration of anti-SARS-CoV-2 spike protein neutralizing monoclonal antibodies (NmAbs) - bamlanivimab (72%) and casirivimab/imdevimab (28%) - efficacy among hematological patients with early-stage COVID-19. Mortality rate was compared to a control cohort of 575 SARS-CoV-2 positive hematological patients untreated with any specific anti-COVID-19 therapy. 88 hematological patients with lymphomas, acute leukemias, and myeloma as their most frequent underlying diagnoses (72%) were evaluated with a 97 days median follow-up after NmAb administration. One third of patients (32%) were treated with an anti-CD20 monoclonal antibody before COVID-19 diagnosis. Median time between first COVID-19 symptom and NmAb administration was 2 days. When administering NmAb, 29%, 57%, 11%, 2%, and 1% of our patients had asymptomatic, mild, moderate, severe, and critical degrees of COVID-19, respectively. 80% of baseline asymptomatic patients remained asymptomatic following NmAb administration. Median duration of COVID-19 symptoms after NmAb administration was 2.5 days. Progression to severe/critical COVID-19 occurred among a total of 17% (15/88) of our cases and numerically higher with bamlanivimab versus casirivimab/imdevimab (21% vs. 8%; p = 0.215), and myelomas (29%), lymphomas (17%) and acute leukemias (18%), respectively. During final follow-up, nine deaths (10%) were recorded - all after bamlanivimab (p = 0.056) with 8% attributed to COVID-19. Regarding "remdesivir/convalescent plasma naïve" patients, COVID-19 mortality rates were significantly lower in our NmAbs treated cohort compared to the control cohort of untreated SARS-CoV-2 positive hematological patients (6% vs. 16%, p = 0.020), respectively. Our study validated the safety and efficacy of NmAbs early use among hematological patients with newly diagnosed early-stage COVID-19 in terms of alleviating infection course and decreasing mortality. Results confirmed a more positive effect of a casirivimab/imdevimab combination versus bamlanivimab monotherapy.
650    _2
$a humanizované monoklonální protilátky $7 D061067
650    _2
$a neutralizující protilátky $7 D057134
650    12
$a COVID-19 $x terapie $7 D000086382
650    _2
$a testování na COVID-19 $7 D000086742
650    _2
$a lidé $7 D006801
650    _2
$a pasivní imunizace $7 D007116
650    _2
$a prospektivní studie $7 D011446
650    12
$a SARS-CoV-2 $7 D000086402
650    _2
$a farmakoterapie COVID-19 $7 D000093485
651    _2
$a Česká republika $7 D018153
655    _2
$a dopisy $7 D016422
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Demel, Ivo $u Department of Haemato-oncology, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Haemato-oncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Víšek, Benjamin $u 4th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Válka, Jan $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Čerňan, Martin $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Jindra, Pavel $u Department of Haematology and Oncology, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Novák, Jan $u Department of Internal Medicine and Haematology, University Hospital Královské Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Stejskal, Lukáš $u Department of Hematology, Silesian Hospital in Opava, Opava, Czech Republic
700    1_
$a Kovácsová, Flóra $u Department of Internal Medicine - Hematology and Oncology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Kabut, Tomáš $u Department of Internal Medicine - Hematology and Oncology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Szotkowski, Tomáš $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Hájek, Roman $u Department of Haemato-oncology, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Haemato-oncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Žák, Pavel $u 4th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Cetkovský, Petr $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Král, Zdeněk $u Department of Internal Medicine - Hematology and Oncology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Mayer, Jiří $u Department of Internal Medicine - Hematology and Oncology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
773    0_
$w MED00002019 $t Hematological oncology $x 1099-1069 $g Roč. 40, č. 2 (2022), s. 280-286
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35120267 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135220 $b ABA008
999    __
$a ok $b bmc $g 1822525 $s 1170211
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 40 $c 2 $d 280-286 $e 20220217 $i 1099-1069 $m Hematological oncology $n Hematol Oncol $x MED00002019
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options